Noble Biomaterials Renews Agreement with KCI for Advanced Wound Care Solutions

Noble Biomaterials, Inc. announced it has renewed its relationship with KCI Manufacturing, an affiliate of Kinetic Concepts, Inc. (KCI), as the antimicrobial technology partner for the companys V.A.C.® GranuFoam Silver® Dressing.  Noble had previously been the technology provider, and this new agreement will continue that relationship for several years.

Our vision is to be the premier provider of bacterial management solutions for health improvement applications, says Jeff Keane, CEO of Noble. This continued partnership supports our mission to improve peoples lives and helps us provide solutions that touch countless patients and their families every day.

Utilizing Nobles proprietary X-STATIC® antimicrobial technology, the V.A.C. ® GranuFoam Silver® Dressing provides an effective barrier to bacterial penetration and may help reduce infection in millions of patients suffering from chronic, acute, sub-acute, traumatic, and dehisced wounds, partial thickness burns, ulcers, flaps and grafts. It was jointly designed and optimized for use with the KCI V.A.C. ® Therapy System to deliver negative pressure to help heal patient wounds.

KCI is a recognized global leader in advanced wound care technology, says Karin Mueller Recchione, vice president of marketing at Noble. And our partnership allows us jointly to deliver the benefits of X-STATIC® technology to patients worldwide.

V.A.C. ® GranuFoam Silver® Dressing allows the silver coated foam pores to come in direct contact with the wound, eliminating the need for additional silver dressing layers. X-STATIC® technology provides 100 percent surface coverage even after sizing the dressing.  It has been shown to inhibit in vitro growth of more than 150 types of microorganisms including common wound pathogens such as Staphylococcus aureus, Streptococcus pyogenes, and Klebsiella pneumonia. In vitro studies have also shown it reduces the growth of antibiotic-resistant strains of bacteria including MRSA and VRE.

X-STATIC® is a proprietary silver-based antimicrobial solution used for mission critical healthcare applications, including advanced wound care, infection control and odor elimination. X-STATIC® is the active ingredient in both FDA-registered and CE-approved products for advanced wound care and has undergone extensive safety testing. X-STATIC® is also a registered antimicrobial agent with the United States Environmental Protection Agency (EPA). In addition to its use in healthcare settings, it is used by Olympic athletes, elite military forces, NASA astronauts and many of the world's premier consumer brands.                                    

X-STATIC® is a registered trademark of Noble Fiber Technologies, LLC. Headquartered in Scranton, PA, Noble Biomaterials, Inc. develops, manufactures and markets advanced antimicrobial technologies designed to manage all forms of bacterial contamination. It has more than 200 global licensees for products in the medical, defense, industrial and consumer markets and the company's headquarters and manufacturing facilities are located in Scranton, PA, with offices in Europe, Asia and South America.

KCI is a leading global medical technology company devoted to understanding, developing and commercializing innovative, high-technology transformational healing solutions for customers and patients in more than 65 countries around the world. Headquartered in San Antonio, Texas, KCI is committed to advancing the science of healing and positively impacting patient care by developing customer-driven innovations to meet the evolving needs of healthcare professionals. Proprietary KCI negative pressure technologies have revolutionized the way in which caregivers treat a wide variety of wound types. The V.A.C.® Therapy System has been used on more than 7 million wounds worldwide.